Back to Results
First PageMeta Content
Nephrogenic systemic fibrosis / Gadopentetic acid / Gadolinium / Magnetic resonance imaging / Pentetic acid / MRI contrast agent / Chemistry / Matter / Gadodiamide


U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may
Add to Reading List

Open Document

File Size: 276,86 KB

Share Result on Facebook

Country

United States / /

MedicalCondition

severe renal insufficiency / internal organ fibrosis Æ / Nephrogenic Systemic Fibrosis / severe renal failure / /

MedicalTreatment

liver transplant / /

Organization

National Science Foundation / U.S. Food and Drug Administration / /

Person

Weinreb / Cowper / Ira Krefting / /

Position

Deputy Director for Safety Division of Medical Imaging and Hematology Products December / Deputy Director for Safety Division of Medical Imaging and Hematology Products / /

Product

Magnevist / Prohance / Multihance / Optimark / Omniscan / /

Technology

MRI / Medical Imaging / /

SocialTag